Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Mar 21;82(8):1387–1392. doi: 10.1054/bjoc.1999.1123

Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden

M Åström 1, L Bodin 2, I Nilsson 3, U Tidefelt 1
PMCID: PMC2363361  PMID: 10780515

Abstract

With the aim of describing an unselected series of acute myeloid leukaemias (AML) in adults, patients diagnosed 1987–1992 in the Örebro region of central Sweden were reviewed by investigating hospital records. By utilizing: (1) The Swedish Cancer Registry, (2) The Cause of Death Registry, (3) listings of pathology bone marrow reports and (4) listings of inpatient discharge diagnoses, we attempted to find all patients. Among secondary AML, only blast-crises of CML were excluded. A total of 214 cases of AML with a median age of 69.5 years were verified corresponding to a mean yearly incidence in adults of 5.4/100 000. Of all patients, 56% had received ‘high-dose’ induction treatment, 28% ‘low-dose’ treatment and 16% no cytostatic treatment. Median survival for all patients was 5.8 months and the probability of survival at 5 years was 9.3%. The 120 ‘high-dose’ treated patients had a total CR rate of 67%, median CR duration 10.1 months and median survival 11.4 months. Age, LDH and kidney function were found to be independent prognostic variables for survival. The inclusion of patients unreferred from district hospitals makes this study unique as an example of unselected AML. © 2000 Cancer Research Campaign

Keywords: AML, survival, selection, prognostic factors

Full Text

The Full Text of this article is available as a PDF (96.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartelink H., Horiot J. C., Poortmans P., Struikmans H., Van den Bogaert W., Barillot I., Fourquet A., Borger J., Jager J., Hoogenraad W. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001 Nov 8;345(19):1378–1387. doi: 10.1056/NEJMoa010874. [DOI] [PubMed] [Google Scholar]
  2. Bassan R., Buelli M., Viero P., Minotti C., Barbui T. The management of acute myelogenous leukemia in the elderly: ten-year experience in 118 patients. Hematol Oncol. 1992 Sep-Oct;10(5):251–260. doi: 10.1002/hon.2900100503. [DOI] [PubMed] [Google Scholar]
  3. Baudard M., Marie J. P., Cadiou M., Viguié F., Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol. 1994 Jan;86(1):82–91. doi: 10.1111/j.1365-2141.1994.tb03256.x. [DOI] [PubMed] [Google Scholar]
  4. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985 Oct;103(4):620–625. doi: 10.7326/0003-4819-103-4-620. [DOI] [PubMed] [Google Scholar]
  5. Bernard P., Reiffers J., Lacombe F., Dachary D., Boisseau M. R., Broustet A. A stage classification for prognosis in adult acute myelogenous leukaemia based upon patients' age, bone marrow karyotype and clinical features. Scand J Haematol. 1984 Apr;32(4):429–440. doi: 10.1111/j.1600-0609.1984.tb00700.x. [DOI] [PubMed] [Google Scholar]
  6. Boros L., Chuang C., Butler F. O., Bennett J. M. Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation. Cancer. 1985 Nov 1;56(9):2161–2169. doi: 10.1002/1097-0142(19851101)56:9<2161::aid-cncr2820560904>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  7. Brincker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep. 1985 Jan;69(1):5–11. [PubMed] [Google Scholar]
  8. DeLima M., Ghaddar H., Pierce S., Estey E. Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol. 1996 Apr;93(1):89–95. doi: 10.1046/j.1365-2141.1996.4771012.x. [DOI] [PubMed] [Google Scholar]
  9. Dutcher J. P., Schiffer C. A., Wiernik P. H. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol. 1987 Sep;5(9):1364–1372. doi: 10.1200/JCO.1987.5.9.1364. [DOI] [PubMed] [Google Scholar]
  10. Estey E., Smith T. L., Keating M. J., McCredie K. B., Gehan E. A., Freireich E. J. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia. 1989 Apr;3(4):257–263. [PubMed] [Google Scholar]
  11. Fenaux P., Preudhomme C., Laï J. L., Morel P., Beuscart R., Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. Br J Haematol. 1989 Sep;73(1):61–67. doi: 10.1111/j.1365-2141.1989.tb00221.x. [DOI] [PubMed] [Google Scholar]
  12. Ferrara F., Mirto S. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol. 1996 Mar;92(3):627–631. doi: 10.1046/j.1365-2141.1996.00398.x. [DOI] [PubMed] [Google Scholar]
  13. Ferrara F., Mirto S., Zagonel V., Pinto A. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymphoma. 1998 Apr;29(3-4):375–382. doi: 10.3109/10428199809068573. [DOI] [PubMed] [Google Scholar]
  14. Hoff P. M., Pierce S., Estey E. Comparison of acute myeloid leukemia patients at MD Anderson: 1982-1986 vs 1992-1996. Leukemia. 1997 Dec;11(12):1997–1998. doi: 10.1038/sj.leu.2400856. [DOI] [PubMed] [Google Scholar]
  15. Johnson P. R., Hunt L. P., Yin J. A. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol. 1993 Oct;85(2):300–306. doi: 10.1111/j.1365-2141.1993.tb03170.x. [DOI] [PubMed] [Google Scholar]
  16. Johnson P. R., Ryder W. D., Yin J. A. Validation of a model to predict survival in elderly patients with acute myeloid leukaemia. Br J Haematol. 1995 Aug;90(4):954–956. doi: 10.1111/j.1365-2141.1995.tb05224.x. [DOI] [PubMed] [Google Scholar]
  17. McKinney P. A., Alexander F. E., Cartwright R. A., Ricketts T. J. The leukaemia research fund data collection survey: the incidence and geographical distribution of acute myeloid leukemia. Leukemia. 1989 Dec;3(12):875–879. [PubMed] [Google Scholar]
  18. Ost A., Lindström P., Christensson B., Gyllenhammar H., Engsted L. Acute leukaemia in a defined geographic area--incidence, clinical history and prognosis. Scand J Haematol. 1984 Aug;33(2):160–170. doi: 10.1111/j.1600-0609.1984.tb02391.x. [DOI] [PubMed] [Google Scholar]
  19. Proctor S. J., Taylor P. R., Stark A., Carey P. J., Bown N., Hamilton P. J., Reid M. M. Evaluation of the impact of allogenic transplant in first remission on an unselected population of patients with acute myeloid leukaemia aged 15-55 years. The Northern Regional Haematology Group. Leukemia. 1995 Jul;9(7):1246–1251. [PubMed] [Google Scholar]
  20. Rowe J. M., Liesveld J. L. Treatment and prognostic factors in acute myeloid leukaemia. Baillieres Clin Haematol. 1996 Mar;9(1):87–105. doi: 10.1016/s0950-3536(96)80038-2. [DOI] [PubMed] [Google Scholar]
  21. Taylor P. R., Reid M. M., Stark A. N., Bown N., Hamilton P. J., Proctor S. J. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. Leukemia. 1995 Feb;9(2):231–237. [PubMed] [Google Scholar]
  22. Wahlin A., Hörnsten P., Jonsson H. Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy. Eur J Haematol. 1991 Apr;46(4):240–247. doi: 10.1111/j.1600-0609.1991.tb00547.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES